Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 5Phase 1 4Phase 3 3Phase 2/3 1

Status

Completed 4Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 2Neoplasm Metastasis 2Polycystic Ovary Syndrome 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × Pharmaceutical Preparations × Clear all
NCT06813118 2026-05-07

Comparison of Clomid and Lezra With Lezra for Ovulation Induction in Clomid Resistant PCOS Case

HITEC-Institute of Medical Sciences

Phase 1 Completed
42 enrolled

Polycystic Ovary Syndrome

NCT00001572 2017-07-02

Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
21 enrolled
Lymphoid

Lymphoma, Follicular, Neoplasms, Lymphoma, B-Cell

NCT01544322 2015-06-18

ME-344-001

MEI Pharma, Inc.

Phase 1 Completed
24 enrolled

Neoplasm Metastasis, Recurrence

NCT01401868 2013-06-24

Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors

MEI Pharma, Inc.

Phase 1 Completed
18 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡